Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children

NCT01006629 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infection
Premature Birth
Bronchopulmonary Dysplasia
Congenital Heart Disease

Interventions

BIOLOGICAL: palivizumab

Sponsor

Abbott